Margriet Bogerd
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Margriet Bogerd has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Jose Paulo Simao Henriques
Department of Cardiology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands
5 shared publications - Alexander Petrus Johannes Vlaar
Department of Intensive Care Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands
3 shared publications - Sanne Ten Berg
Amsterdam UMC
3 shared publications Adriaan O Kraaijeveld
Department of Cardiology, Utrecht University Medical Center , Utrecht
2 shared publications- Annemarie E. Engstrom
Amsterdam UMC
2 shared publications - Elma J Peters
Department of Cardiology, Heart Center, Amsterdam University Medical Center , Meibergdreef 9, Amsterdam 1105 AZ
2 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19) , e049767
Reinforcing Culprit‐Only Revascularization for Acute Myocardial Infarction‐Related Cardiogenic Shock: Insights From the Netherlands Heart Registration
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19) , e049767
Open AccessReinforcing Culprit‐Only Revascularization for Acute Myocardial Infarction‐Related Cardiogenic Shock: Insights From the Netherlands Heart Registration
- Open Access
- 6 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (9) , e042149
Impella‐Protected High‐Risk Percutaneous Coronary Intervention in the Elderly: Balancing Feasibility and Necessity
- 6 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (9) , e042149
Open AccessImpella‐Protected High‐Risk Percutaneous Coronary Intervention in the Elderly: Balancing Feasibility and Necessity
- Open Access
- 25 March 2025
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 14 (6) , 327-341
Development and validation of a risk score in acute myocardial infarction-related cardiogenic shock
Aims: Mortality in patients with acute myocardial infarction-related cardiogenic shock (AMICS) is high, but a widely accepted tool for individual risk assessment is lacking. A reliable prediction model could assist in clinical decision-making, patient selection for clinical trials, and comparison of AMICS populations. Therefore, the aim of this study was to develop and externally validate a prediction model for 30-day mortality in AMICS patients. Methods and results: This retrospective cohort study included patients from 2017 to 2021 (development cohort) and 2010–2017 (validation cohort). Patients with AMICS undergoing percutaneous coronary intervention in The Netherlands were identified using the Netherlands Heart Registration. International validation was performed in the Danish Retroshock registry. The main outcome was 30-day mortality. Among 2261 patients, the median age was 67 years [interquartile range (IQR) 58–75], and 1649 (73%) were male. The mortality rate at 30 days was 39% (n = 886). Significant predictors for mortality were: initial lactate, glucose, renal function, haemoglobin, age, blood pressure, heart rate, intubation prior to PCI, intervention in the left main coronary artery, and successful revascularization. The AUC of the initial model was 0.81 (0.79–0.83). The external validation cohort included 1393 patients with 1050 (75%) male and a median age of 67 years (IQR 59–75). The 30-day mortality rate was 49% (n = 680). The model showed good performance on the external validation with an AUC of 0.73 (0.70–0.76). Conclusion: A prediction model was developed and externally validated using data from two large national registries. The model demonstrated good performance and is suitable for clinical decision-making and quality purposes in AMICS.
- 25 March 2025
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 14 (6) , 327-341
Open AccessDevelopment and validation of a risk score in acute myocardial infarction-related cardiogenic shock
Aims: Mortality in patients with acute myocardial infarction-related cardiogenic shock (AMICS) is high, but a widely accepted tool for individual risk assessment is lacking. A reliable prediction model could assist in clinical decision-making, patient selection for clinical trials, and comparison of AMICS populations. Therefore, the aim of this study was to develop and externally validate a prediction model for 30-day mortality in AMICS patients. Methods and results: This retrospective cohort study included patients from 2017 to 2021 (development cohort) and 2010–2017 (validation cohort). Patients with AMICS undergoing percutaneous coronary intervention in The Netherlands were identified using the Netherlands Heart Registration. International validation was performed in the Danish Retroshock registry. The main outcome was 30-day mortality. Among 2261 patients, the median age was 67 years [interquartile range (IQR) 58–75], and 1649 (73%) were male. The mortality rate at 30 days was 39% (n = 886). Significant predictors for mortality were: initial lactate, glucose, renal function, haemoglobin, age, blood pressure, heart rate, intubation prior to PCI, intervention in the left main coronary artery, and successful revascularization. The AUC of the initial model was 0.81 (0.79–0.83). The external validation cohort included 1393 patients with 1050 (75%) male and a median age of 67 years (IQR 59–75). The 30-day mortality rate was 49% (n = 680). The model showed good performance on the external validation with an AUC of 0.73 (0.70–0.76). Conclusion: A prediction model was developed and externally validated using data from two large national registries. The model demonstrated good performance and is suitable for clinical decision-making and quality purposes in AMICS.
- Open Access
- 17 February 2025
- Published by BMJ in Open Heart
- Vol. 12 (1) , e002846
Clinical use and impact of mechanical circulatory support for myocardial infarction-related cardiogenic shock in the Netherlands: a registry-based propensity-matched analysis
Background: Despite limited beneficial evidence, mechanical circulatory support (MCS) is commonly used in patients with acute myocardial infarction-related cardiogenic shock (AMI-CS). In this Dutch registry, we investigated MCS usage, associated patient characteristics and clinical outcomes. Methods: This real-world, multicentre registry included CS patients undergoing percutaneous coronary intervention between 2017 and 2021 in 14 Dutch hospitals. The impact on clinical outcomes was analysed after 1:1 average propensity-score (aPS) matching. Results: This AMI-CS registry included 2217 patients with a mean age of 66.4 (±12.3) years and predominantly male (72.8%, n=1613). MCS was deployed in 516 patients (23.3%), of which the intra-aortic balloon pump was used most frequently (n=253, 49.0%). Impella was used in 94 patients (18.2%), extracorporeal membrane oxygenation in 68 patients (13.2%) and 95 patients (18.4%) received multiple devices. Patients receiving MCS were younger (64.2 vs 67.0, p<0.01), presented with lower mean arterial pressures (74.7 vs 78.4 mm Hg, p<0.01), higher heart rates (88.3 vs 81.7 beats per minute, p<0.01) and higher initial lactate levels (6.4 vs 5.4 mmol/L, p<0.01). The percentage of resuscitated patients was comparable among MCS and non-MCS patients (38.6% vs 42.2%, p=0.17). The 30-day mortality rate was higher in MCS patients (55.0% vs 34.7%, p<0.01). After aPS-matching (n=970), 30-day mortality remained higher for MCS patients (53.8% vs 44.7%, p<0.01), with an associated OR of 1.44 (95% CI 1.12 to 1.85, p<0.01). Conclusions: Despite limited evidence, MCS was used in a fourth of all AMI-CS patients. MCS usage was associated with an increased 30-day mortality in this real-world setting, even after propensity-matching.
- 17 February 2025
- Published by BMJ in Open Heart
- Vol. 12 (1) , e002846
Open AccessClinical use and impact of mechanical circulatory support for myocardial infarction-related cardiogenic shock in the Netherlands: a registry-based propensity-matched analysis
Background: Despite limited beneficial evidence, mechanical circulatory support (MCS) is commonly used in patients with acute myocardial infarction-related cardiogenic shock (AMI-CS). In this Dutch registry, we investigated MCS usage, associated patient characteristics and clinical outcomes. Methods: This real-world, multicentre registry included CS patients undergoing percutaneous coronary intervention between 2017 and 2021 in 14 Dutch hospitals. The impact on clinical outcomes was analysed after 1:1 average propensity-score (aPS) matching. Results: This AMI-CS registry included 2217 patients with a mean age of 66.4 (±12.3) years and predominantly male (72.8%, n=1613). MCS was deployed in 516 patients (23.3%), of which the intra-aortic balloon pump was used most frequently (n=253, 49.0%). Impella was used in 94 patients (18.2%), extracorporeal membrane oxygenation in 68 patients (13.2%) and 95 patients (18.4%) received multiple devices. Patients receiving MCS were younger (64.2 vs 67.0, p<0.01), presented with lower mean arterial pressures (74.7 vs 78.4 mm Hg, p<0.01), higher heart rates (88.3 vs 81.7 beats per minute, p<0.01) and higher initial lactate levels (6.4 vs 5.4 mmol/L, p<0.01). The percentage of resuscitated patients was comparable among MCS and non-MCS patients (38.6% vs 42.2%, p=0.17). The 30-day mortality rate was higher in MCS patients (55.0% vs 34.7%, p<0.01). After aPS-matching (n=970), 30-day mortality remained higher for MCS patients (53.8% vs 44.7%, p<0.01), with an associated OR of 1.44 (95% CI 1.12 to 1.85, p<0.01). Conclusions: Despite limited evidence, MCS was used in a fourth of all AMI-CS patients. MCS usage was associated with an increased 30-day mortality in this real-world setting, even after propensity-matching.
- Open Access
- 12 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 14 (5) , 279-287
Resource utilization associated with extracorporeal membrane oxygenation vs. microaxial flow pump for infarct-related cardiogenic shock
Aims: Microaxial flow pump and venoarterial extracorporeal membrane oxygenation (VA-ECMO) are increasingly used in infarct-related cardiogenic shock. This study provides a comparative overview of real-world resource utilization associated with these devices (PROSPERO: CRD42024505174). Methods and results: EMBASE, MEDLINE, and Cochrane Library were sought from inception to 13 November 2024 for studies reporting at least one primary outcome, including intensive care unit (ICU) length of stay (LOS), hospital LOS, in-hospital costs, and discharge destination. In-hospital mortality was included as secondary outcome. This study was guided by the PRISMA-2020 guideline. Study selection and data extraction were independently performed by two researchers. Risk-of-bias assessments were done using the Newcastle-Ottawa-Scale. Data were pooled using random-effect models. In total, 12 retrospective cohorts were identified encompassing 92 262 microaxial flow pump- and 16 474 VA-ECMO patients data. The meta-analysis of hospital LOS and in-hospital costs revealed favourable results for the microaxial flow pump, with mean differences (MD) of −5.3 days (95% CI: −6.6, −4.1) and −$113 983 (95% CI: −$143 153, −$84 812), respectively. Microaxial flow pump survivors were also 45% more likely to be discharged home (95% CI: 1.28–1.64). Intensive care unit-length of stay was reported by one study, reporting a 10 days MD in favour of the microaxial flow pump. The averaged in-hospital mortality rates were 44% and 57% for the microaxial flow pump and VA-ECMO, respectively. An inherent limitation of observational studies is confounding by indication. Conclusion: Microaxial flow pump was associated with lower resource utilization compared with VA-ECMO. Resource utilization should be incorporated in prospective RCTs and taken into account when considering these devices.
- 12 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 14 (5) , 279-287
Open AccessResource utilization associated with extracorporeal membrane oxygenation vs. microaxial flow pump for infarct-related cardiogenic shock
Aims: Microaxial flow pump and venoarterial extracorporeal membrane oxygenation (VA-ECMO) are increasingly used in infarct-related cardiogenic shock. This study provides a comparative overview of real-world resource utilization associated with these devices (PROSPERO: CRD42024505174). Methods and results: EMBASE, MEDLINE, and Cochrane Library were sought from inception to 13 November 2024 for studies reporting at least one primary outcome, including intensive care unit (ICU) length of stay (LOS), hospital LOS, in-hospital costs, and discharge destination. In-hospital mortality was included as secondary outcome. This study was guided by the PRISMA-2020 guideline. Study selection and data extraction were independently performed by two researchers. Risk-of-bias assessments were done using the Newcastle-Ottawa-Scale. Data were pooled using random-effect models. In total, 12 retrospective cohorts were identified encompassing 92 262 microaxial flow pump- and 16 474 VA-ECMO patients data. The meta-analysis of hospital LOS and in-hospital costs revealed favourable results for the microaxial flow pump, with mean differences (MD) of −5.3 days (95% CI: −6.6, −4.1) and −$113 983 (95% CI: −$143 153, −$84 812), respectively. Microaxial flow pump survivors were also 45% more likely to be discharged home (95% CI: 1.28–1.64). Intensive care unit-length of stay was reported by one study, reporting a 10 days MD in favour of the microaxial flow pump. The averaged in-hospital mortality rates were 44% and 57% for the microaxial flow pump and VA-ECMO, respectively. An inherent limitation of observational studies is confounding by indication. Conclusion: Microaxial flow pump was associated with lower resource utilization compared with VA-ECMO. Resource utilization should be incorporated in prospective RCTs and taken into account when considering these devices.